1. Home
  2. DGICA vs IRWD Comparison

DGICA vs IRWD Comparison

Compare DGICA & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DGICA

Donegal Group Inc.

HOLD

Current Price

$16.21

Market Cap

607.2M

Sector

Finance

ML Signal

HOLD

Logo Ironwood Pharmaceuticals Inc.

IRWD

Ironwood Pharmaceuticals Inc.

HOLD

Current Price

$4.33

Market Cap

663.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DGICA
IRWD
Founded
1986
1998
Country
United States
United States
Employees
851
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
607.2M
663.6M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
DGICA
IRWD
Price
$16.21
$4.33
Analyst Decision
Hold
Buy
Analyst Count
1
3
Target Price
$19.00
$7.67
AVG Volume (30 Days)
80.9K
1.6M
Earning Date
04-30-2026
05-11-2026
Dividend Yield
4.14%
N/A
EPS Growth
N/A
1400.00
EPS
N/A
0.15
Revenue
N/A
$298,276,000.00
Revenue This Year
$2.26
$57.95
Revenue Next Year
N/A
$4.39
P/E Ratio
$7.82
$29.60
Revenue Growth
N/A
8.88
52 Week Low
$16.29
$0.55
52 Week High
$21.06
$5.78

Technical Indicators

Market Signals
Indicator
DGICA
IRWD
Relative Strength Index (RSI) 36.01 58.89
Support Level N/A $3.80
Resistance Level $17.75 $4.50
Average True Range (ATR) 0.39 0.25
MACD -0.11 0.02
Stochastic Oscillator 20.47 79.49

Price Performance

Historical Comparison
DGICA
IRWD

About DGICA Donegal Group Inc.

Donegal Group Inc is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty insurance in 21 Mid-Atlantic, Midwestern, Southern, and Southwestern states. It includes three segments: Investments Function, Commercial Lines of Insurance, and Personal Lines of Insurance. The majority of revenue is from the commercial Lines segment. The commercial Lines segment consists mainly of commercial automobile, commercial multi-peril, and workers' compensation policies.

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

Share on Social Networks: